# KIZOO Technology Capital

> KIZOO Technology Capital is a VC fund backing Biotechnology and Health Care. See 55 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Karlsruhe, Germany
- Total investments: 55
- Last investment: Sep 2025
- Lead investor: 45%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/kizoo
- X (Twitter): http://twitter.com/Kizoo
- Website: http://www.kizoo.com
- Facebook: http://www.facebook.com/kizooventures

KIZOO Technology Capital is a VC fund in Karlsruhe focused on Biotechnology and Health Care. KIZOO provides mentoring, seed and early-stage financing with a focus on rejuvenation biotech. Having been entrepreneurs, VCs and mentors in both, high growth tech and biotech companies theirselves for many years with multiple exits and massive value created for the founders, they now bring this experience to the emerging field of rejuvenationbiotech - a young industry that will eventually become much bigger than today's largest technology markets. ​ As part of the Forever Healthy Group, they directly support the creation of startups that turn research on the root causes of aging into therapies and services for humans. ​ Forever Healthy's other initiatives include the evaluation of new rejuvenation therapies, evidenced-based curation of the world's cutting-edge medical knowledge, funding research projects on the root causes of aging and hosting the annual Undoing Aging Conference.

## Contacts

5 contacts available for KIZOO Technology Capital. Shizune tracks 3 team members at KIZOO Technology Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/kizoo?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $658k–$10M |
| Series A | $1.5M–$3.2M |
| Series B | $8.5M–$10M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 13 | 24% |
| Health Care | 7 | 13% |
| Therapeutics | 7 | 13% |
| Biopharma | 6 | 11% |
| Life Science | 5 | 9% |

45 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 24 | 44% |
| Series A | 7 | 13% |
| Series B | 4 | 7% |
| Funding Round | 3 | 5% |
| Pre-Seed | 1 | 2% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 15 | 27% |
| Germany | 12 | 22% |
| United Kingdom | 2 | 4% |
| Austria | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Frank Schueler | Managing Director | 27 | https://shizune.co/investors/profile/frank-schler |
| Michael Greve | Owner | 1 | https://shizune.co/investors/profile/michael-greve |
| Matthias Hornberger | CFO | 7 | https://shizune.co/investors/profile/matthias-hornberger |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cellvie | Cellvie develops cell-derived medicines, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell.Mitochondria are at the heart of complex life's origin. Likely a bacterium at the time, the would-be-organelle merged with a simple organism, entering into a symbiotic relationship: The mitochondria began supplying theenergy for elaborate cellular functions to evolve, while the organism provided the mitochondria with an environment to thrive. Today, mitochondria are found in all human cells, except for red blood cells. They take on a pivotal role in cellular fate, as they produce most of the energy (ATP) and are involved in a large number of cellular and metabolic processes. The density of the organelles is particularly high in cells requiring a lot of cellular energy - e.g. cardiomyocytes or brain cells.Mitochondria function, and hence energy supply to the cell, may be impaired due to acute insults (e.g. ischemia) or genetic disorders (e.g. LOHN).Researchers at Harvard University developed an approach for mitochondria augmentation and replacement to ameliorate the damages from ischemia-reperfusion injury. Ischemia is a lack of blood flow leading to an undersupply of oxygen and an impairment of mitochondria function. Reperfusion describes the re-introduction of blood flow, inducing an oversupply of oxygen. Both, ischemia and reperfusion, damage cells, with the mitochondria dysfunction being at the heart of the injury. The cascade of events, from ischemia to reperfusion, will eventually lead to cell death. The most prominent acute conditions associated with ischemia-reperfusion injury are heart attacks. At Cellvie, we are developing a means to transplant viable mitochondria into the compromised cells, to interrupt the said cascade of events, re-enabling the cells to turn oxygen into energy via the mitochondria. | $5M | Seed | Sep 09, 2025 |  |
| Reservoir Neuroscience | Reservoir Neuroscience is a biopharma company that develops novel therapeutics to repair dysfunctional blood vessels in the brain. Reservoir Neuroscience was founded in 2019 and is based in Emeryville, California. | $4M | Venture - Series Unknown | Jan 18, 2024 |  |
| Cellvie | Cellvie develops cell-derived medicines, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell.Mitochondria are at the heart of complex life's origin. Likely a bacterium at the time, the would-be-organelle merged with a simple organism, entering into a symbiotic relationship: The mitochondria began supplying theenergy for elaborate cellular functions to evolve, while the organism provided the mitochondria with an environment to thrive. Today, mitochondria are found in all human cells, except for red blood cells. They take on a pivotal role in cellular fate, as they produce most of the energy (ATP) and are involved in a large number of cellular and metabolic processes. The density of the organelles is particularly high in cells requiring a lot of cellular energy - e.g. cardiomyocytes or brain cells.Mitochondria function, and hence energy supply to the cell, may be impaired due to acute insults (e.g. ischemia) or genetic disorders (e.g. LOHN).Researchers at Harvard University developed an approach for mitochondria augmentation and replacement to ameliorate the damages from ischemia-reperfusion injury. Ischemia is a lack of blood flow leading to an undersupply of oxygen and an impairment of mitochondria function. Reperfusion describes the re-introduction of blood flow, inducing an oversupply of oxygen. Both, ischemia and reperfusion, damage cells, with the mitochondria dysfunction being at the heart of the injury. The cascade of events, from ischemia to reperfusion, will eventually lead to cell death. The most prominent acute conditions associated with ischemia-reperfusion injury are heart attacks. At Cellvie, we are developing a means to transplant viable mitochondria into the compromised cells, to interrupt the said cascade of events, re-enabling the cells to turn oxygen into energy via the mitochondria. | $5.5M | Seed | Feb 06, 2023 |  |
| Mogling Bio | Mogling Bio is developing novel pharmacological approaches to rejuvenate old stem cells. |  | Seed | Oct 26, 2022 |  |
| Elastrin Therapeutics | Elastrin Therapeutics is a biotech startup with technologies to restore hardened and damaged arteries & tissue by targeting the elastic fiber that makes them work.The company's proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improvesthe efficacy of drugs and eliminates side effects by combining particle design with elastin targeting. | $10M |  | Apr 07, 2022 |  |
| Elastrin Therapeutics | Elastrin Therapeutics is a biotech startup with technologies to restore hardened and damaged arteries & tissue by targeting the elastic fiber that makes them work.The company's proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improvesthe efficacy of drugs and eliminates side effects by combining particle design with elastin targeting. | $10M | Seed | Apr 07, 2022 |  |
| Elastrin Therapeutics | Elastrin Therapeutics is a biotech startup with technologies to restore hardened and damaged arteries & tissue by targeting the elastic fiber that makes them work.The company's proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improvesthe efficacy of drugs and eliminates side effects by combining particle design with elastin targeting. | $10M | Seed | Apr 07, 2022 |  |
| Revel Pharmaceuticals | Revel develops therapeutics for multiple diseases of aging including osteoarthritis, kidney disease, cardiovascular disease, skin aging, and complications of diabetes. It is commercializing therapeutic enzymes to degrade age-associated molecule damage. It was founded in 2019 and is based in San Francisco, California. | $8.4M | Seed | Mar 17, 2022 |  |
| Cyclarity Therapeutics | Underdog Pharmaceuticals is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting toxic forms of cholesterol, using rationally designed molecules, to provide the first true disease-modifying treatments for age-related diseases such as atherosclerosis,hypercholesterolemia, heart failure, and macular degeneration.Its products are based on novel derivatives of a well-known, safe compound, and a new way of looking at cardiovascular disease created through a SENS Research Foundation program. | $10M | Seed | Sep 23, 2021 |  |
| Staffbase | Staffbase provides an internal communications platform to help companies and their employees work together toward a common goal. Staffbase supports industry leaders with their own branded app to engage their diverse, disconnected, and distributed workforce. The company was founded in 2014 and is headquartered in Chemnitz with offices in Dresden,Cologne, and New York. | $143.6M | Series D | Mar 29, 2021 |  |

10 of 55 investments shown.

## Co-investors
- [Capnamic](https://shizune.co/investors/profile/capnamic-ventures) — VC Fund, 10 deals together
- [General Atlantic](https://shizune.co/investors/profile/general-atlantic) — VC Fund, 6 deals together
- [Headline](https://shizune.co/investors/profile/headlinevc) — VC Fund, 6 deals together
- [Insight Partners](https://shizune.co/investors/profile/insight-partners) — VC Fund, 3 deals together
- [Runa Capital](https://shizune.co/investors/profile/runa-capital) — VC Fund, 3 deals together
- [SC Launch, Inc.](https://shizune.co/investors/profile/sc-launch) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [Accel](https://shizune.co/investors/profile/accel) — VC Fund
- [SV Angel](https://shizune.co/investors/profile/sv-angel) — VC Fund
- [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund
- [HV Capital](https://shizune.co/investors/profile/holtzbrinck-ventures) — VC Fund
- [IBB Ventures](https://shizune.co/investors/profile/ibb) — VC Fund

## Featured in investor lists
- [Enterprise VC Funds in Germany](https://shizune.co/investors/enterprise-vc-funds-germany)
- [Hardware VC Funds in Germany](https://shizune.co/investors/hardware-vc-funds-germany)
- [Hardware Investors in Germany](https://shizune.co/investors/hardware-investors-germany)
- [FinTech VC Funds in Germany](https://shizune.co/investors/fintech-vc-funds-germany)
- [Enterprise Software Investors in Germany](https://shizune.co/investors/enterprise-software-investors-germany)
- [Hospitality Investors in Germany](https://shizune.co/investors/hospitality-investors-germany)

## FAQ

### What does KIZOO Technology Capital invest in?

KIZOO Technology Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Seed and Series A stage. Most of the 55 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is KIZOO Technology Capital's check size?

KIZOO Technology Capital typically joins rounds of $658k–$10M at Seed, $1.5M–$3.2M at Series A and $8.5M–$10M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds KIZOO Technology Capital participates in.

### How do I contact KIZOO Technology Capital?

Public channels for KIZOO Technology Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at KIZOO Technology Capital?

The team at KIZOO Technology Capital includes Frank Schueler (Managing Director), Michael Greve (Owner) and Matthias Hornberger (CFO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co